Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Haisco: The company's independently developed oral small-molecule agonist drug HSK55879 has been approved for clinical trials
Recently, Haishike announced that its subsidiary, Shanghai Haishike Shengnuo Pharmaceutical Technology Co., Ltd., received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration. After review, the IND applications for HSK55879 tablets for two indications, accepted in December 2025, meet the relevant requirements for drug registration, and clinical trials are approved to proceed. HSK55879 tablets are a new generation oral small-molecule agonist developed independently by the company, with proprietary intellectual property rights, intended for the treatment of metabolic system diseases.
(Haishike Announcement)
(Editor: Yang Yan, Lin Chen)
Keywords: Medical